IRCT20250316065096N1 IRCT 2025-05-10 Ghoum University of Medical Sciences The effect of Empagliflozin on non-alcoholic fatty liver disease Studying the effect of EMPAGLIFLOZIN on non-alcoholic fatty liver disease and liver fibrosis in type 2 diabetic patients 2025-05-22 anticipated 70 Complete https://irct.ir/trial/82721 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The allocation of individuals will be done using simple block randomization. The block size is considered to be 4. Therefore, we will have six blocks of four consisting of AABB, ABAB, BBAA, BABA, ABBA, BAAB. The selection of each block will also be random and will be done using a dice roll. For example, if the number 3 comes up in the dice roll, block BBAA is considered and therefore the first two patients will be assigned to treatment B and the next two patients to treatment A. The dice roll will continue until the allocation of patients to treatment groups is completed. Also, the allocation of treatment to groups A and B will also be done based on chance (random number table). 3 Nonalcoholic steatohepatitis (NASH). Intervention 1: Intervention group: , After obtaining consent, eligible individuals were randomly selected In addition to standard diabetes treatment, they receive the drug empagliflozin at a dose of 10 mg ( Abidi Company) once a day for 6 months. Intervention 2: Control group: After obtaining consent, eligible individuals will be randomly assigned to receive a placebo drug without empagliflozin once daily for 6 months in addition to standard diabetes treatment. No - There is not a plan to make this available Justification or reason for not sharing IPD is Its release schedule is not yet known